MATERNUS-Kliniken AG (MAK) AI Stock Analysis

• Market Cap: €23.07M
• Dividend Yield: N/A
• Average Volume (3M): 559.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 11.43%
• EPS Growth: 7.72%
• Country: DE
• Employees: 1,452
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 20,970,000
• 10 Day Avg. Volume: 260
• 30 Day Avg. Volume: 559
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.00
• Price Target Upside: -9.09% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: €1.00 ▼(-9.09% Downside)

The overall stock score reflects significant financial challenges, with persistent losses and high leverage being the most impactful factors. Technical analysis shows a bearish trend, and valuation metrics are weak due to negative earnings and no dividend yield. The lack of earnings call and corporate events data limits further insights.

MATERNUS-Kliniken AG Business Overview & Revenue Model

Company Description

MATERNUS-Kliniken AG (MAK) is a leading healthcare provider in Germany, specializing in rehabilitation and acute care services. With a focus on high-quality medical treatment and patient-centered care, the company operates several clinics that provide a range of services, including orthopedic rehabilitation, neurological rehabilitation, and psychosomatic therapy. MAK is dedicated to enhancing patient outcomes through innovative therapies and a multidisciplinary approach, positioning itself as a key player in the healthcare sector.

How the Company Makes Money

MATERNUS-Kliniken AG generates revenue primarily through the provision of healthcare services, which are funded by a combination of health insurance reimbursements and out-of-pocket payments from patients. The company's core revenue streams include inpatient and outpatient rehabilitation services, consultation fees, and specialized treatment programs. Additionally, MAK may benefit from partnerships with health insurance companies, government health programs, and other healthcare organizations that facilitate patient referrals and enhance service offerings. By maintaining high occupancy rates in its clinics and continuously improving service efficiency, the company is able to optimize its earnings and ensure sustainable financial growth.

MATERNUS-Kliniken AG Financial Statement Overview

Summary

The company faces significant financial challenges with persistent losses and high leverage. Despite a slight revenue growth and strong gross profit margin, the negative net profit margin and negative equity highlight financial instability. Improvement in cash flow is a positive sign, but overall, the financial position remains precarious.

Income Statement

The company has shown a slight revenue growth of 4.87% in the latest year, but it continues to struggle with profitability, evidenced by a negative net profit margin of -11.54% and a negative EBIT margin of -1.62%. The gross profit margin remains strong at 86.65%, indicating efficient cost management at the gross level. However, the persistent negative net income suggests challenges in managing operating expenses and interest costs.

Balance Sheet

The balance sheet reveals significant financial leverage with a debt-to-equity ratio of -2.47, indicating high reliance on debt financing. The negative stockholders' equity suggests financial instability and potential solvency issues. Return on equity is not meaningful due to negative equity, and the equity ratio is negative, highlighting a precarious financial position.

Cash Flow

Cash flow analysis shows improvement with a free cash flow growth rate of 51.05%, indicating better cash generation capabilities. The operating cash flow to net income ratio of 0.11 suggests that cash flows are not fully covering net losses, but the free cash flow to net income ratio of 0.92 shows a positive trend in cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	108.71M	114.00M	102.31M	106.70M	111.44M	114.30M
Gross Profit	13.45M	98.78M	87.45M	86.98M	97.52M	97.70M
EBITDA	5.66M	10.71M	4.71M	1.71M	14.96M	13.21M
Net Income	-6.88M	-13.16M	-14.26M	-14.08M	-2.48M	-9.62M
Balance Sheet
Total Assets	150.59M	139.88M	154.38M	153.40M	165.41M	178.63M
Cash, Cash Equivalents and Short-Term Investments	3.59M	4.94M	8.05M	5.20M	13.58M	11.41M
Total Debt	186.53M	165.41M	112.35M	170.31M	168.99M	181.36M
Total Liabilities	204.53M	206.72M	206.49M	192.70M	193.26M	204.03M
Stockholders Equity	-55.60M	-66.84M	-53.76M	-39.30M	-27.85M	-25.41M
Cash Flow
Free Cash Flow	9.17M	13.86M	-1.44M	2.33M	15.32M	11.43M
Operating Cash Flow	14.69M	15.07M	2.52M	4.33M	17.24M	12.17M
Investing Cash Flow	-5.53M	-1.07M	-3.96M	-2.00M	-1.92M	-702.00K
Financing Cash Flow	-9.85M	-11.68M	7.46M	-12.76M	-12.79M	-2.23M

MATERNUS-Kliniken AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MAK, the sentiment is Negative. The current price of 1.1 is below the 20-day moving average (MA) of 1.13, below the 50-day MA of 1.21, and below the 200-day MA of 1.40, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.85 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:MAK.

MATERNUS-Kliniken AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M12	74 Outperform	265.23M	14.85	15.10%	3.52%	6.52%	7.17%
MED	70 Outperform	141.55M	4.17	14.64%	1.34%	4.27%	―
LIK	64 Neutral	109.20M	23.22	16.98%	―	0.21%	7.53%
MAK	43 Neutral	€23.07M	―	―	―	11.43%	7.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%